Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

4.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk and protective factors for musculoskeletal injury in youth track and field: a methodological scoping review.

BMC sports science, medicine & rehabilitation·2026
Same author

Cross-study analysis identifies estrogen depletion and exposure duration as key determinants of bisphenol A transcriptomic potency in MCF-7 cells.

Toxicology reports·2026
Same author

Effects of plyometric training on performance-related metrics in track and field athletes: a systematic review and meta-analysis of randomized controlled trials, with preliminary evidence on injury prevention.

BMC sports science, medicine & rehabilitation·2026
Same author

Dermatologic conditions associated with HIV among US adults across different racial and ethnic groups: A retrospective cohort study using TriNetX.

Journal of the American Academy of Dermatology·2026
Same author

Evaluation of Type 1 Error Rates in Duplex Sequencing for Mutagenicity Testing Using Vehicle Control Data and Simulation Analyses.

Environmental and molecular mutagenesis·2026
Same author

Prevalence and incidence of fibromyalgia and associated severity in the United States using MarketScan.

Pain reports·2026

Related Experiment Video

Updated: May 4, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

10.4K

Oncologists' attitudes toward KRAS testing: a multisite study.

Julie N Harris1, Petra Liljestrand, Gwen L Alexander

  • 1Division of Research, Kaiser Permanente Northern California, Oakland, California.

Cancer Medicine
|January 10, 2014
PubMed
Summary
This summary is machine-generated.

Oncologists rapidly adopted Kirsten ras (KRAS) testing for metastatic colorectal cancer (mCRC) treatment decisions. The KRAS test is considered useful, fulfilling an important need for personalized anticancer therapy.

Keywords:
Cancer geneticscolorectal cancerpsychosocial studies

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: May 4, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

10.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Translational Research

Background:

  • Personalized anticancer therapy relies on molecular tumor characteristics.
  • Kirsten ras (KRAS) mutation testing is a key diagnostic for metastatic colorectal cancer (mCRC).

Purpose of the Study:

  • To examine oncologists' adoption of KRAS testing.
  • To understand how KRAS test results influence treatment discussions with mCRC patients.

Main Methods:

  • 34 semi-structured interviews with oncologists across seven health plans.
  • Qualitative analysis of audiotaped, transcribed interviews.
  • Thematic summarization of physician experiences with KRAS testing.

Main Results:

  • All interviewed oncologists reported using KRAS testing.
  • Rapid adoption observed, often within 6 months of national guideline publication.
  • Most oncologists ordered KRAS tests upon mCRC diagnosis; consensus on test utility and patient benefits.

Conclusions:

  • Rapid KRAS test adoption indicates it meets a critical informational need for oncologists.
  • KRAS testing supports tailored treatment strategies for mCRC.
  • Future research should explore patient understanding and confidence in KRAS-guided treatment decisions.